Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001 Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Childhood B-ALL patients, including those with VHR features, had favorable outcomes on DFCI 05-001 risk-stratified therapy. IKZF1 deletion was an independent predictor of inferior outcome, including among patients with low end-induction MRD.

authors

Vrooman, Lynda M
Blonquist, Traci M
Harris, Marian H
Stevenson, Kristen E
Place, Andrew E
Hunt, Sarah K
O’Brien, Jane E
Asselin, Barbara L
Athale, Uma
Clavell, Luis A
Cole, Peter D
Kelly, Kara M
Laverdiere, Caroline
Leclerc, Jean-Marie
Michon, Bruno
Schorin, Marshall A
Sulis, Maria Luisa
Welch, Jennifer JG
Neuberg, Donna S
Sallan, Stephen E
Silverman, Lewis B

status

published

publication date

June 26, 2018

has subject area

Adolescent (MeSH)
Age Factors (MeSH)
Child (MeSH)
Child, Preschool (MeSH)
Clinical Trials, Phase III as Topic (MeSH)
Female (MeSH)
Histone-Lysine N-Methyltransferase (MeSH)
Humans (MeSH)
Ikaros Transcription Factor (MeSH)
Infant (MeSH)
Leukocyte Count (MeSH)
Male (MeSH)
Multicenter Studies as Topic (MeSH)
Multivariate Analysis (MeSH)
Myeloid-Lymphoid Leukemia Protein (MeSH)
Neoplasm, Residual (MeSH)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (MeSH)
Randomized Controlled Trials as Topic (MeSH)
Risk Assessment (MeSH)
Risk Factors (MeSH)
Survival Analysis (MeSH)

published in

Blood Advances Journal